Breaking News, Collaborations & Alliances

Lonza, Agennix In Talactoferrin Manufacturing Pact

Lonza to produce commercial material at its facility in the Czech Republic

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Lonza and Agennix AG have entered an agreement for the production of Agennix’s oral Dendritic Cell Mediated Immunotherapy (DCMI), talactoferrin, currently in Phase III testing for the treatment of non-small cell lung cancer (NSCLC). Lonza will produce commercial material at its microbial manufacturing facility in Kourim, Czech Republic. This agreement initiates the process needed to seek approval for Lonza as a second manufacturer of talactoferrin after the initial commercial launch. &#82...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters